about
Lipid, blood pressure and kidney update 2013.The Effect of Diet on the Survival of Patients with Chronic Kidney Disease.Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal DiseasesMarkers of increased cardiovascular risk in patients with chronic kidney disease.Assessment of the relationship between lipid parameters and obesity indices in non-diabetic obese patients: a preliminary report.The multi-biomarker approach for heart failure in patients with hypertension.Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease.Molecular mechanisms of statin intoleranceBlood pressure levels and stroke: J-curve phenomenon?Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease.PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.Radioisotopic assessment of bone metabolism of the operated vertebra after inter-process stabilizer implantation in the lumbar segment of the spine.Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study.The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection.Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction.Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome.Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease.Hypertension - Current Natural Strategies to Lower Blood Pressure.The Use of Plant Sterols and Stanols as Lipid-Lowering Agents in Cardiovascular Disease.Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease.Qualification for endoscopic retrograde cholangiopancreatography in the diagnosis and treatment of extrahepatic cholestasis caused by choledocholithiasis.Erratum to: Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk.Telomere attrition, kidney function, and prevalent chronic kidney disease in the United States.Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients.The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis.Biomarkers of cardiovascular risk in haemodialysis patients.The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease.Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients.The occurrence of atrial fibrillation in dialysis patients and its association with left atrium volume before and after dialysis.Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients.Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic surveyProsarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart FailureAre Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert PanelEvaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney DiseaseEstablished and potential echocardiographic markers of embolism and their therapeutic implications in patients with ischemic strokeCholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome
P50
Q33574532-97A98160-30D7-4782-84A0-43422E930773Q33749490-D2183C5A-01F4-432E-9EFB-62B9EE045005Q33838866-0C5A3DF0-9453-4E3A-9C48-8031A2CE4BAFQ34582124-D57766FC-0AA5-43EA-8346-86E6CCC22089Q34742982-0E17A44A-6B68-4B25-895D-177E89BE8CD7Q35723466-6640F1F3-8B6F-4EE6-BB73-0F1CC499216FQ36538088-26ACEBEB-EA5D-4E3D-B1F3-62BCF39F6AC1Q36681249-B83360CB-5E09-45B9-BC0C-002369178D6FQ36958324-2FF8575D-45A2-4153-9B2C-35F3216159E4Q37337561-560F5E9D-E91C-4287-9C4F-A62DC3560C94Q37517937-4B128B0C-26C3-4B5E-98A7-EBB2D0C88E63Q37549374-188D360B-BDFD-412C-89B9-01E8DD7D6919Q37549397-A11C6DCB-B38A-41D9-9DB3-926EB4C9089CQ37579475-0E50E2EE-208E-4181-9A39-D50D49F19D7CQ38123004-45DECA44-013B-4BA7-B4D7-6B17B140A254Q38217985-812276A0-D73E-499B-A2E1-D790371507E7Q38615348-63A1E24C-AB9F-438B-9D51-CCFC697B9742Q38646836-3CE23CF3-B229-43E2-9A51-5F5164F95B1BQ38960067-10FCC0FF-25B6-45CD-9A78-FF832C5A707CQ39142446-A161C038-4489-4292-A19C-5D4A6F17BDF5Q39182448-81676844-32C1-4F89-BCE6-06D66B327283Q39255411-5F58C33F-A6B6-4D72-ABA6-7B6F46F43FFAQ41453993-C5916FEF-AED5-4F8F-9216-A12E20462968Q42925169-986B849C-E69D-481B-BEB6-4FF35F5A33BBQ44819479-EB3DD1A7-1B43-4384-A5B2-FADDEF0FB03CQ45792365-B8675868-9BB6-452C-B437-651D4D5F3920Q47219920-529D863F-CFC4-4570-80E4-C4303292E835Q47858886-BF6EDC0A-E154-4E3F-BA76-F79D5D175CF8Q47944999-A78A9F6C-5207-49B0-AC67-4A254DCE2AFFQ48883042-61A2E4DA-8191-453C-97AD-91741A70CD47Q51367188-2F5D40C7-3E18-462C-A1E9-4A0F3F5F945DQ52901309-061BC6B3-8FA0-4DC1-9181-5C5A2CFAD881Q55515176-AD7C1AC4-11C5-469D-B083-F659DAC110E7Q57806503-8E16BF90-D310-48FD-A6EF-E0A999E4BD71Q59683761-A941FDE7-F36B-4241-9807-D8F2E1D4E52EQ59683920-3D381A04-16E8-4BC9-9C35-42D3F374C114Q59684216-4AA52959-DD65-499C-9521-AE1936FDAC05Q87063223-D0EFA2A7-33D8-42CD-B567-6DDE1AAFF34DQ88541932-F90CFF37-B808-4326-9C69-74DEF695E246Q88935943-00970BB5-5264-4FA3-A55F-D0318DE32D26
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Jacek Rysz
@en
Jacek Rysz
@nl
type
label
Jacek Rysz
@en
Jacek Rysz
@nl
prefLabel
Jacek Rysz
@en
Jacek Rysz
@nl
P31
P496
0000-0002-2757-6443